Cervical Dystonia Market Report and Forecast 2024-2032

Cervical Dystonia Market Report and Forecast 2024-2032


Cervical Dystonia Market Report and Forecast 2024-2032

The cervical dystonia market size is projected to grow at a compound annual growth rate (CAGR) of 5.8% during the forecast period of 2024-2032. The key drivers of the market growth are the increasing awareness and diagnosis of cervical dystonia, the rising demand for botulinum toxin injections, the development of novel therapies and devices, and the growing geriatric population.

Cervical dystonia, also known as spasmodic torticollis, is a rare and chronic condition that affects the muscles of the neck, causing them to twist and tilt in abnormal postures. It can cause pain, discomfort, and difficulty in performing daily activities. The exact cause of cervical dystonia is unknown, but it may be related to genetic factors, environmental triggers, or brain abnormalities. The prevalence of cervical dystonia is estimated to be between 57 and 280 per million people worldwide, with a higher incidence in women and older age groups. The diagnosis of cervical dystonia is based on clinical examination and medical history, and the treatment options include oral medications, botulinum toxin injections, surgery, and physical therapy.

Cervical Dystonia Epidemiology

The epidemiology of cervical dystonia in the market is influenced by several factors, such as the geographic distribution, the age and gender distribution, the diagnostic criteria, and the data sources. According to a systematic review and meta-analysis by Epidemiology International, the global prevalence of cervical dystonia was 158.67 per million people, with a 95% confidence interval (CI) of 94.38-222.96, based on 29 studies from 16 countries. The prevalence was higher in Europe (193.77 per million) than in North America (120.77 per million) and Asia (86.43 per million). The prevalence was also higher in women (228.77 per million) than in men (88.57 per million), and in older age groups (40-59 years: 235.96 per million; 60-79 years: 392.92 per million) than in younger age groups (20-39 years: 59.82 per million; <20 years: 10.59 per million). The diagnosis of cervical dystonia was based on various criteria, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), the International Classification of Diseases (ICD), or the clinical judgment of physicians. The data sources included population-based surveys, hospital-based registries, or insurance databases.

Cervical Dystonia Market Drivers and Constraints
  • Increasing awareness and diagnosis of cervical dystonia: The awareness and recognition of cervical dystonia as a distinct neurological disorder has improved in recent years, leading to more accurate and timely diagnosis of the condition. This has resulted in increased demand for treatment and support services for patients with cervical dystonia. Moreover, the availability of diagnostic tools such as electromyography (EMG) and genetic testing has facilitated the identification and classification of cervical dystonia subtypes, which may help in tailoring the treatment to individual needs and preferences.
  • Rising demand for botulinum toxin injections: Botulinum toxin injections are the mainstay of treatment for cervical dystonia, as they can reduce muscle spasms and improve the posture and quality of life of the patients. Botulinum toxin injections are available in four types: A (Botox, Dysport, Xeomin), B (Myobloc, Neurobloc), C, and D. Among them, type A is the most widely used and has the longest duration of action. The global botulinum toxin market was valued at USD 4.7 billion in 2019 and is expected to grow at a CAGR of 7.5% from 2020 to 2027, driven by the increasing applications of botulinum toxin in various therapeutic and cosmetic areas, including cervical dystonia.
  • Development of novel therapies and devices: Besides botulinum toxin injections, there are several other therapies and devices that are being developed or investigated for the treatment of cervical dystonia. These include oral medications such as dopamine agonists, anticholinergics, benzodiazepines, and cannabinoids; intrathecal baclofen pumps; deep brain stimulation (DBS); transcranial magnetic stimulation (TMS); and ultrasound-guided percutaneous radiofrequency ablation. These therapies and devices aim to provide more effective, safe, and convenient options for patients with cervical dystonia who are refractory to or intolerant of botulinum toxin injections or oral medications.
  • Growing geriatric population: The prevalence of cervical dystonia increases with age, and the condition is more common in older adults than in younger ones. According to the World Health Organization (WHO), the global population aged 60 years and over was 962 million in 2017 and is expected to double to 2.1 billion by 2050. As the aging population grows, so does the potential market for cervical dystonia treatment, as more people may develop or seek treatment for the condition.
  • High cost of treatment: The treatment of cervical dystonia can be expensive, especially for botulinum toxin injections and surgical procedures. The average cost of a single botulinum toxin injection for cervical dystonia in the US ranges from USD 300 to USD 600, depending on the dose and type of botulinum toxin used. The cost of DBS surgery for cervical dystonia can range from USD> 50,000 to USD 100,000, depending on the location and complexity of the procedure. These costs may pose a significant burden for patients and their families, especially in low- and middle-income countries, where access to affordable and quality health care is limited.
  • Adverse effects of medications and injections: The medications and injections used for cervical dystonia can cause various side effects, such as dry mouth, nausea, drowsiness, headache, pain, swelling, bruising, infection, weakness, dysphagia, and dysphonia. In some cases, these side effects can be severe or life-threatening, such as allergic reactions, botulinum toxin spread, or hemorrhage. These side effects may affect the compliance and satisfaction of the patients and limit the use of certain medications and injections for cervical dystonia treatment.
  • Lack of reimbursement policies: The reimbursement policies for cervical dystonia treatment vary widely across different countries and regions, and often depend on the type and severity of the condition, the availability and efficacy of the treatment, and the insurance coverage and regulations. In some countries, such as the US, Canada, and Australia, botulinum toxin injections are covered by public or private health insurance plans for cervical dystonia, but the coverage may be partial or subject to certain conditions and limitations. In other countries, such as India, China, and Brazil, botulinum toxin injections are not covered by any health insurance plans and have to be paid out-of-pocket by the patients. The lack of reimbursement policies may deter some patients from seeking or continuing treatment for cervical dystonia, especially if they have low income or limited resources.
Cervical Dystonia Market Trends and Developments
  • Emergence of gene therapy:
Phase I clinical trial of AXO-AAV-GM2, developed by Axovant Gene Therapies, to evaluate safety and efficacy in patients with cervical dystonia. Expected to enroll 12 patients and complete by 2023.
  • Launch of new devices and technologies
In 2020, Medtronic received FDA approval for its Percept PC neurostimulator, a DBS device that can monitor and record brain signals while delivering electrical stimulation to targeted areas. Indicated for the treatment of cervical dystonia, among other neurological disorders.
  • Expansion of botulinum toxin market
Key factors driving market growth include increasing demand for cosmetic and therapeutic applications, approval of new products and indications, and rising disposable income and medical tourism.

Cervical Dystonia Market Segmentation

Market Breakup by Type
  • Retrocollis
  • Anterocollis
  • Laterocollis
  • Torticollis
  • Others
Market Breakup by Therapy
  • Oral Therapy
  • Intravenous
  • Surgery
  • Others
Market Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
Germany

France

Italy

Spain

United Kingdom
  • Japan
  • China
Cervical Dystonia Market Competitive Landscape

The key players in the market include AbbVie Inc., Ipsen Pharma, Galderma SA, Revance Therapeutics Inc., AEON Biopharma, Merz Pharmaceuticals, US World Meds, Tercica Inc., Boston Scientific Corporation, Allergan Inc., and Solstice neurosciences lnc. These players are engaged in various strategies, such as product launches and approvals, mergers and acquisitions, collaborations and partnerships, research and development, and expansion, to gain a competitive edge and increase their market share.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cervical Dystonia Market Overview – 8 Major Markets
3.1 Cervical Dystonia Market Historical Value (2017-2023)
3.2 Cervical Dystonia Market Forecast Value (2024-2032)
4 Cervical Dystonia Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Cervical Dystonia Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
6.5 China Cervical Dystonia Epidemiology Scenario and Forecast (2017-2032)
7 Cervical Dystonia Market Landscape – 8 Major Markets
7.1 Cervical Dystonia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cervical Dystonia: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Therapy
8 Cervical Dystonia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Cervical Dystonia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Cervical Dystonia Market Segmentation (2017-2032) - 8 Major Markets
11.1 Cervical Dystonia Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Retrocollis
11.1.3 Anterocollis
11.1.4 Laterocollis
11.1.5 Torticollis
11.1.6 Others
11.2 Cervical Dystonia Market (2017-2032) by Therapy
11.2.1 Market Overview
11.2.2 Oral Therapy
11.2.3 Intravenous
11.2.4 Surgery
11.2.5 Others
11.3 Cervical Dystonia Market (2017-2032) by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Homecare
11.3.4 Specialty Clinics
11.3.5 Others
11.4 Cervical Dystonia Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 China
12 United States Cervical Dystonia Market (2017-2032)
12.1 United States Cervical Dystonia Market Historical Value (2017-2023)
12.2 United States Cervical Dystonia Market Forecast Value (2024-2032)
12.3 United States Cervical Dystonia Market (2017-2032) by Type
12.3.1 Market Overview
12.3.2 Medication
12.3.3 Organ Transplantation
12.3.4 Oxygen Therapy
12.3.5 Others
12.4 United States Cervical Dystonia Market (2017-2032) by Therapy
12.4.1 Market Overview
12.4.2 Idiopathic pulmonary fibrosis
12.4.3 Hepatic cirrhosis
12.4.4 Renal fibrosis
12.4.5 Cutaneous fibrosis
12.4.6 Others
13 EU-4 and United Kingdom Cervical Dystonia Market (2017-2032)
13.1 EU-4 and United Kingdom Cervical Dystonia Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Cervical Dystonia Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Dystonia Market (2017-2032) by Type
13.3.1 Market Overview
13.3.2 Medication
13.3.3 Organ Transplantation
13.3.4 Oxygen Therapy
13.3.5 Others
13.4 EU-4 and United Kingdom Dystonia Market (2017-2032) by Therapy
13.4.1 Market Overview
13.4.2 Idiopathic pulmonary fibrosis
13.4.3 Hepatic cirrhosis
13.4.4 Renal fibrosis
13.4.5 Cutaneous fibrosis
13.4.6 Others
14 Japan Cervical Dystonia Market
14.1 Japan Cervical Dystonia Market Historical Value (2017-2023)
14.2 Japan Cervical Dystonia Market Forecast Value (2024-2032)
14.3 Japan Cervical Dystonia Market (2017-2032) by Type
14.3.1 Market Overview
14.3.2 Medication
14.3.3 Organ Transplantation
14.3.4 Oxygen Therapy
14.3.5 Others
14.4 Japan Cervical Dystonia Market (2017-2032) by Therapy
14.4.1 Market Overview
14.4.2 Idiopathic pulmonary fibrosis
14.4.3 Hepatic cirrhosis
14.4.4 Renal fibrosis
14.4.5 Cutaneous fibrosis
14.4.6 Others
15 China Cervical Dystonia Market
15.1 China Cervical Dystonia Market (2017-2032) Historical Value (2017-2023)
15.2 China Cervical Dystonia Market (2017-2032) Forecast Value (2024-2032)
15.3 China Cervical Dystonia Market (2017-2032) by Type
15.3.1 Market Overview
15.3.2 Medication
15.3.3 Organ Transplantation
15.3.4 Oxygen Therapy
15.3.5 Others
15.4 China Cervical Dystonia Market (2017-2032) by Therapy
15.4.1 Market Overview
15.4.2 Idiopathic pulmonary fibrosis
15.4.3 Hepatic cirrhosis
15.4.4 Renal fibrosis
15.4.5 Cutaneous fibrosis
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 AbbVie Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Ipsen Pharma
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Galderma SA
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Revance Therapeutics Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 AEON Biopharma
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Merz Pharmaceuticals
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 US World Meds
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Tercica Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Boston Scientific Corporation
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Allergan Inc.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Solstice neurosciences lnc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
List not exhaustive
23 Cervical Dystonia Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
*The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings